Structure Therapeutics Inc.

GPCR

US86366E1064

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
74.92 ^USD	+2.34%		-15.30%	+7.72%

02-04	Wall Street ends sharply down as traders fret about AI disruption	RE
02-03	Wall Street ends sharply down as traders fret about AI disruption	RE

Structure Therapeutics Inc - Gasherbrum entered agreement with Genentech and Roche - SEC filing

Published on 01/05/2026 at 10:19 pm GMT

Reuters

Latest news about Structure Therapeutics Inc.

02-04	Wall Street ends sharply down as traders fret about AI disruption	RE
02-03	Wall Street ends sharply down as traders fret about AI disruption	RE
02-03	Wall Street tumbles as traders fret about AI disruption	RE
02-03	Wall St selloff deepens led by software, cloud firms	RE
02-03	Obesity stocks slump on Novo's underwhelming 2026 sales forecast	RE
01-14	Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030	RE
01-09	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026	RE
01-05	Structure Therapeutics Inc - Gasherbrum entered agreement with Genentech and Roche - SEC filing	RE
12-23	Top pharma companies racing to launch first weight-loss pill	RE
12-23	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-17	Structure Therapeutics Inc. Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity	CI
12-17	Structure Therapeutics Starts Phase 1 Trial of Oral Obesity Treatment	MT
12-17	Structure Therapeutics starts phase 1 study of oral amylin agonist ACCG-2671	RE
12-12	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-10	Structure Therapeutics Prices $650 Million Upsized Public Offering	MT
12-08	Health Care Down Amid Intensified Obesity-Drug Competition - Health Care Roundup	DJ
12-08	Structure Therapeutics Plans $500 Million Public Offering	MT
12-08	Top Midday Gainers	MT
12-08	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT
12-08	Top Midday Stories: Paramount Launches $30-per-Share Bid for Warner Bros. Discovery; IBM to Acquire Confluent in $11 Billion Deal	MT
12-08	Structure Therapeutics Shares Surge on Positive Phase 2b Results for Obesity Drug Aleniglipron	MT
12-08	Structure Therapeutics Weight-Loss Pill Achieves 11-15 Percent Reduction in Phase 2 Trial - BN	FW
12-08	Structure Therapeutics Inc. - Special Call
12-08	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-08	Why the Fed's Next Move Matters More Than Markets Admit

Chart Structure Therapeutics Inc.

Duration

Period

GPCR: Dynamic Chart

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.

Employees

218

Sector

Biotechnology & Medical Research

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company